معرفی
Professor Adam Todd is a faculty member at Newcastle University, specializing in clinical pharmacology and geriatric medicine. His research focuses on optimizing medication use in older adults, particularly deprescribing practices, polypharmacy management, and healthcare disparities. He has led studies exploring palliative care decision-making, vaccination equity, and the role of community pharmacies in public health. Todd's work frequently addresses systemic inequalities in healthcare access and outcomes, with notable contributions to understanding medication adherence and unmet needs in cancer patients. His collaborative projects span multidisciplinary teams and include randomized controlled trials evaluating interventions like smoking cessation programs and psychological support services. Todd also contributes to policy discussions on pharmacy care distribution and the impact of urban development on health equity.
Education & Affiliations: While specific educational details are not provided, Todd's extensive publication record indicates a strong academic background in pharmacy and clinical research. He collaborates with multiple departments at Newcastle University and external institutions, including Public Health England and other national healthcare bodies.
Research Highlights: Todd’s work bridges clinical practice and public health, with key themes including:
- Deprescribing strategies in frail elderly populations
- Socioeconomic factors influencing cancer treatment access
- Improving medication safety in community pharmacies
- Leveraging technology for public health surveillance
Grants & Collaborations: Todd leads and participates in funded projects addressing polypharmacy, palliative care, and health disparities. Notable collaborations include work with Professors Clare Bambra (health inequalities) and Andy Husband (pharmacy practice).
Labs/Teams: Active in Newcastle’s Institute of Health & Society and the School of Pharmacy & Biomedical Sciences, Todd contributes to interdisciplinary initiatives like the PULSE cohort study and the PharmOA osteoarthritis management project.
